The innovative platform antibody drug is designed based on the TAM receptors, which are key signaling pathways regulating cell homeostasis. It induces phagocytosis without triggering
inflammatory or neuroinflammatory responses, thereby minimizing side effects caused by inflammation. Additionally, it improves the functions of immune cells such as glial cells and
macrophages, enabling the development of novel drugs for degenerative brain diseases and immune disorders that existing antibody drugs have not been able to overcome.